Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of...

Full description

Bibliographic Details

Published in:	Expert opinion on investigational drugs Vol. 9; no. 12; pp. 2903 - 2911
Main Author:	Kelland, Lloyd R
Format:	Journal Article
Language:	English
Published:	England Ashley Publications Ltd 01.12.2000 Taylor & Francis
Subjects:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use cancer Clinical Trials as Topic cyclin-dependent kinase Cyclin-Dependent Kinases - antagonists & inhibitors Flavonoids - pharmacology Flavonoids - therapeutic use flavopiridol Humans inhibitor Neoplasms - drug therapy Piperidines - pharmacology Piperidines - therapeutic use
ISSN:	1354-3784, 1744-7658
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!